[1]李金霞,指导:曹洪欣.基于复杂网络的温心方治疗冠状动脉狭窄机制研究[J].中国中医药信息杂志,2019,26(6):101-105.[doi:10.3969/j.issn.1005-5304.2019.06.021]
 LI Jinxia,Instructor: CAO Hongxin.Study on Mechanism of Wenxin Decoction in Treating Coronary Artery Stenosis Based on Complex Network[J].zhongguo zhongyiyao xinxi zazhi,2019,26(6):101-105.[doi:10.3969/j.issn.1005-5304.2019.06.021]
点击复制

基于复杂网络的温心方治疗冠状动脉狭窄机制研究

参考文献/References:

[1] 曹洪欣,张明雪.试论冠心病病机与阳虚痰瘀[J].中医药通报,2002, 1(6):1-3.
[2] 曹洪欣,张华敏.痰瘀互结与冠心病发病机理辨识[J].中医药学刊, 2001,19(6):544-545.
[3] 曹洪欣,殷惠军,张腾.温心胶囊抗动脉粥样硬化的形态学研究[J].中国中医药科技,2001,8(1):39.
[4] 李同达.温阳益心活血化痰法对冠状动脉粥样硬化大鼠血管内皮保护作用研究[D].北京:中国中医科学院,2014.
[5] WANG J, LI X J. Drug targets discovery based on dynamic signal transduction networks[J]. Acta Pharm Sin,2010,45(1):1-8.
[6] BARABáSI A L, GULBAHCE N, LOSCALZO J. Network medicine:a network-based approach to human disease[J]. Nat Rev Genet, 2011,12(1):56-68.
[7] LI J, ZHAO P, LI Y, et al. Systems pharmacology-based dissection of mechanisms of Chinese medicinal formula Bufei Yishen as an effective treatment for chronic obstructive pulmonary disease[J]. Sci Rep,2015,5(10):15290.
[8] WANG X, WANG Q, ZHANG A, et al. Metabolomics study of intervention effects of Wen-Xin-Formula using ultra high- performance liquid chromatography/mass spectrometry coupled with pattern recognition approach[J]. J Pharm Biomed Anal,2013, 74(2):22-30.
[9] WANG S L, WANG H B, LU Y. Tianfoshen oral liquid:a CFDA approved clinical traditional chinese medicine, normalizes major cellular pathways disordered during colorectal carcinogenesis[J]. Oncotarget,2017,8(9):14549-14569.
[10] BARABáSI A L, OLTVAI Z N. Network biology:understanding the cell’s functional organization[J]. Nat Rev Genet,2004,5(2):101? 113.
[11] HOPKINS A L. Network pharmacology[J]. Nat Biotechnol,2007, 25:1110-1111.
[12] 向铮,蔡小军,曾苏.基于复杂网络与代谢组学的中药药代动力学研究思考与探讨[J].药学学报,2012,47(5):558-564.
[13] 李从林,王博龙.基于网络药理学的益母草作用机制分析[J].中国中医药信息杂志,2018,25(12):102-106.
[14] 魏金婷,刘文奇.植物药活性成分β-谷甾醇研究概况[J].莆田学院学报,2007,14(2):38-40,46.
[15] 王敏,刘保林,国旭丹.槲皮素及其代谢物抑制氧化应激与炎症[J]. 食品科学,2013,34(15):256-260.
[16] 张腾,曹洪欣,盛小禹,等.温心胶囊对大鼠实验性缺血心肌细胞凋亡及Bcl-2、Fas蛋白表达的影响[J].中国中西医结合杂志,2003,23(10):769-771.
[17] 唐丹丽,曹洪欣,张华敏.温阳益心法对动脉粥样硬化大鼠主动脉MCP-I、NF-kB表达的影响[J].中国中医基础医学杂志,2007,13(2):110- 112.
[18] 唐丹丽,曹洪欣,张华敏.温阳益心法对动脉粥样硬化大鼠血清C反应蛋白和白细胞介素-6水平的影响[J].中国中医药信息杂志,2007,14(7):29-30.
[19] 张明雪,曹洪欣.温心胶囊对冠心病心阳虚证大鼠血小板形态MPV, PDW值的影响[J].中药新药与临床药理,2005,16(1):30-33.
[20] 张明雪,曹洪欣.温阳活血化痰法降低冠心病心阳虚证血小板聚集率的机制探讨[J].中国中西医结合急救杂志,2003,10(2):84-86.
[21] 张明雪,曹洪欣.温心胶囊对冠心病心阳虚证大鼠血小板功能的影响[J].中国急救医学,2002,22(10):563-564.
[22] 沈雁,曹洪欣,周景华,等.实验性心力衰竭大鼠心肌细胞细胞间黏附分子1的表达[J].中国临床康复,2005,9(39):30-32.
[23] 冯玲,曹洪欣,胡元会,等.温阳益心方对大鼠心悸梗死模型心脏促血管新生的机制研究[J].中国中医基础医学杂志,2009,15(4):274-276.(收稿日期:2018-10-24)(修回日期:2019-03-25;编辑:向宇雁)

备注/Memo

基金项目:唐仲英中药基金会资助项目(2013-2023)
通讯作者:曹洪欣,E-mail:caohx898@163.com

更新日期/Last Update:

2019-05-21